CERT on Nasdaq

Certara, Inc.

We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development (“MIDD”) in the global biopharmaceutical and biotech industry.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with AvePoint, Avid Technology or Grid Dynamics Holdings, or pick any stock.

  • TickerCERT on Nasdaq2
  • IndustryServices-Prepackaged Software2
  • HeadquartersPrinceton, United States2
  • Incorporated inDE3
  • Business address4 Radnor Corporate Center, Suite 350, Radnor, Pa 190873
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • Kind of organizationLimited partnership2
  • LEI549300EZJTHTM78UD6952
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 43112962

See how the biggest companies compare on our leaderboards

We are a global leader in biosimulation science, technology, and consulting services for using Model-Informed Drug Development (“MIDD”) in the global biopharmaceutical and biotech industry. MIDD is an approach that utilizes biological and statistical models derived from preclinical, clinical, and evidence data to inform decision-making in drug research and development, and commercialization. Biosimulation is a critical component of MIDD that uses computer-aided mathematical simulation of biological processes and systems to understand the action of a drug in a human body or a population of humans.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

5.0%Operating margin5
-0.4%Net margin5
8.7%Revenue growth, 20255
-0.2%Return on equity5
0.27×Debt to equity5
$94.6MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

Americas brought in 70% of the revenue Certara, Inc. broke down this way in fiscal 2025.

  1. Americas$291.6M570%up 4% from 2024
  2. EMEA$92.6M522%up 21% from 2024
  3. Asia Pacific$34.6M58%up 28% from 2024
Regions by year
Regions202320242025
Americas$265.1M$281.5M$291.6M
EMEA$63.6M$76.6M$92.6M
Asia Pacific$25.7M$27.1M$34.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development10¢$41.0M
  • Other costs88¢$368.6M
  • Income tax2¢$9.2M

Out of $418.8M in revenue.5 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending2¢$1.8M
  • Share buybacks44¢$42.6M
  • Kept or used elsewhere54¢$52.0M

Out of $96.3M of cash from operations.5

Financial statements

Revenue67895$418.8M in 2025+101% since 2019
0$200.0M$400.0M$600.0M2019: $208.5M$208.5M20192020: $243.5M$243.5M2020+17%2021: $286.1M$286.1M2021+17%2022: $335.6M$335.6M2022+17%2023: $354.3M$354.3M2023+6%2024: $385.1M$385.1M2024+9%2025: $418.8M$418.8M2025+9%
Operating income67895$21.0M in 2025+7% since 2019
-$60.0M-$40.0M-$20.0M0$20.0M$40.0M2019: $19.6M$19.6M20192020: -$24.4M-$24.4M20202021: $13.6M$13.6M20212022: $32.5M$32.5M2022+139%2023: -$40.8M-$40.8M20232024: -$1.7M-$1.7M2024−96%2025: $21.0M$21.0M2025
Net income67895-$1.6M in 2025−82% since 2019
-$60.0M-$40.0M-$20.0M0$20.0M2019: -$8.9M-$8.9M20192020: -$49.4M-$49.4M2020+453%2021: -$13.3M-$13.3M2021−73%2022: $14.7M$14.7M20222023: -$55.4M-$55.4M20232024: -$12.1M-$12.1M2024−78%2025: -$1.6M-$1.6M2025−87%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Revenues$418.8M$385.1M$354.3M
Cost of revenues$161.1M$154.5M$141.0M
Sales and marketing$53.7M$47.4M$32.0M
Research and development$41.0M$37.1M$34.2M
General and administrative$85.4M$94.2M$95.4M
Depreciation and amortization$56.6M$53.6M$45.5M
Goodwill impairment expense$0$0$47.0M
Total operating expenses$236.7M$232.4M$254.1M
Income (loss) from operations$21.0M-$1.7M-$40.8M
Interest expense-$19.7M-$21.5M-$22.9M
Net other income$6.3M$6.1M$8.5M
Total other expenses-$13.4M-$15.5M-$14.4M
Income (loss) before income taxes$7.6M-$17.2M-$55.1M
Provision (benefit) for income taxes$9.2M-$5.1M$214.0K
Net loss-$1.6M-$12.1M-$55.4M
Foreign currency translation adjustment, net of tax of $6, $(956), $(717)$18.9M-$3.2M$2.7M
Change in fair value of interest rate swap, net of tax of $253, $$(827), $1,393-$3.4M-$2.6M-$2.1M
Total other comprehensive income (loss)$15.5M-$5.8M$637.0K
Comprehensive income (loss)$13.9M-$17.9M-$54.7M
Basic (in dollars per share)-$0.01-$0.08-$0.35
Diluted (in dollars per share)-$0.01-$0.08-$0.35
Basic (in shares)160.4M shares160.4M shares158.9M shares
Diluted (in shares)160.4M shares160.4M shares158.9M shares
Foreign currency translation adjustment, tax expense (benefit)$6.0K-$956.0K-$717.0K
Change in fair value from interest rate swap, tax expense (benefit)$253.0K-$827.0K$1.4M

Compare Certara, Inc. with another company

Leadership

Who has led Certara, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. William F. Feehery2020–2026
  2. Jon Matthew Resnick2026–now

President

  1. Leif E. Pedersen2020–2021
  2. Robert Aspbury2020–2021
  3. Craig R. Rayner2021
  4. Drayton Virkler2022–2023
  5. Adrian McKemey2025
  6. John E. Gallagher2025–now

Chief financial officer

  1. Michael Andrew Schemick2020–2023
  2. John E. Gallagher2023–2026
  3. John W. Reynders V.2026
  4. Faiz Mohammed2026–now
2025
Board members and other officers (22)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Human Resources OfficerNicolette Sherman named Mar 27, 202444
  • Presdient, Certara Drug Development SolutionsPatrick Smith named Mar 27, 202444
  • DirectorMatthew Walsh named Mar 27, 2024 to Apr 28, 202645

Timeline

  1. Jan 12, 2026New chief executive Jon Matthew Resnick becomes CEO12
  2. Dec 11, 2020New chief executive William F. Feehery becomes CEO13
  3. Mar 2, 2007Founded Certara, Inc. is founded2

Filings

339 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 51 major events, 195 insider forms, 24 large holders, 3 private raises, 45 other. The latest 20:

  1. Sep 3, 2026144 EDGAR
  2. Sep 2, 20264 EDGAR
  3. Aug 7, 20268-K EDGAR
  4. Aug 4, 202610-Q EDGAR
  5. Aug 4, 20268-K EDGAR
  6. Aug 4, 20268-K EDGAR
  7. Jul 17, 20263 EDGAR
  8. Jul 14, 2026SCHEDULE 13G/A EDGAR
  9. Jul 8, 2026SCHEDULE 13G/A EDGAR
  10. Jun 17, 20268-K EDGAR
  11. Jun 2, 20264 EDGAR
  12. Jun 2, 20264 EDGAR
  13. May 15, 20264 EDGAR
  14. May 15, 20264 EDGAR
  15. May 15, 20264 EDGAR
  16. May 15, 20264 EDGAR
  17. May 15, 20264 EDGAR
  18. May 15, 20264 EDGAR
  19. May 15, 20264 EDGAR
  20. May 15, 20264 EDGAR

The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

74 open-market trades by officers, directors and large owners since October 2021: 5 buys and 69 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 11, 2025Feehery William FCHIEF EXECUTIVE OFFICERBuy24,096$8.30$200.0KForm 4
Sep 9, 2025Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFFSale51,224$10.92$559.4KForm 4
Oct 7, 2024SMITH PATRICK FPRESIDENT, DRUG DEV SOLUTIONSSale5,409$11.03$59.7KForm 4
Sep 9, 2024Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFFSale51,224$11.29$578.3KForm 4
Apr 2, 2024SMITH PATRICK FPRESIDENT, DRUG DEV SOLUTIONSSale14,427$16.85$243.2KForm 4
Apr 1, 2024Traynor Richard M.SVP AND GENERAL COUNSELSale3,000$18.00$54.0KForm 4
Mar 4, 2024Traynor Richard M.SVP AND GENERAL COUNSELSale3,000$18.28$54.8KForm 4
Feb 20, 2024SMITH PATRICK FPRESIDENT, DRUG DEV SOLUTIONSSale5,000$18.00$90.0KForm 4
Feb 12, 2024Traynor Richard M.SVP AND GENERAL COUNSELSale6,000$18.00$108.0KForm 4
Dec 26, 2023Traynor Richard M.SVP AND GENERAL COUNSELSale6,000$18.00$108.0KForm 4
Sep 11, 2023Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFFSale51,224$14.60$747.9KForm 4
Aug 22, 2023BROSHY ERANDirectorBuy4,807$15.80$76.0KForm 4
Aug 21, 2023BROSHY ERANDirectorBuy193$16.10$3.1KForm 4
Jun 5, 2023SMITH PATRICK FPRESIDENT, DRUG DEV SOLUTIONSSale19,104$21.55$411.7KForm 4
May 11, 2023Traynor Richard M.SVP AND GENERAL COUNSELSale5,000$20.82$104.1KForm 4
Apr 14, 2023Traynor Richard M.SVP AND GENERAL COUNSELSale5,000$23.66$118.3KForm 4
Mar 6, 2023Traynor Richard M.SVP AND GENERAL COUNSELSale10,000$21.45$214.5KForm 4
Feb 2, 2023Traynor Richard M.SVP AND GENERAL COUNSELSale15,000$20.00$300.0KForm 4
Dec 8, 2022EQT Fund Management S.a r.l.10% ownerSale29,954,521$15.00$449.3MForm 4
Nov 22, 2022Pedersen Leif EPRESIDENT, CHIEF COMMERCAL OFFSale51,223$15.55$796.5KForm 4

All 74 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 15, 2026Raised $8.6 million in a private offering of equity Form D: 6 investors so far Form D
  2. Mar 24, 2025Raised $5.7 million in a private offering of equity Form D: 6 investors so far Form D
  3. Mar 27, 2024Filed a private offering of equity Form D: named in the filing: Cynthia Collins, Patrick Smith, Rosemary Crane, Nancy Killefer, Nicolette Sherman, Eran Broshy Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.18,818,180$123.3M0.0%+4,510,302
Deerfield Management Company, L.P.7,512,928$49.2M0.6%−295,677
Haveli Investment Management LLC7,400,000$48.5M26.9%New
Jefferies Financial Group Inc.7,091,051$46.4M0.4%+232,842
Vanguard Portfolio Management LLC7,056,106$46.2M0.0%+1,086,910
Dimensional Fund Advisors LP6,022,686$39.4M0.0%−2,539,822
Vanguard Capital Management LLC5,283,180$34.6M0.0%−77,249
State Street Corp4,821,805$31.6M0.0%+881,310
Wasatch Advisors LP4,298,825$28.2M0.2%−973,341
Geode Capital Management, LLC3,141,689$20.6M0.0%+1,027,133
Fort Washington Investment Advisors Inc /oh/2,864,204$18.8M0.1%+188,661
Royce & Associates LP2,756,026$18.1M0.1%+1,540,975
UBS Group AG2,666,456$17.5M0.0%−754,176
Millennium Management LLC2,555,126$16.7M0.0%+1,299,182
Morgan Stanley2,551,111$16.7M0.0%−689,106
First Trust Advisors LP2,424,222$15.9M0.0%+1,508,738
Aqr Capital Management LLC2,160,167$13.8M0.0%+1,589,441
Ameriprise Financial Inc2,030,844$13.3M0.0%−217,015
Systematic Financial Management LP1,892,050$12.4M0.2%New
Kopion Asset Management, LLC1,858,539$12.2M7.7%+570,087
Bank Of America Corp /de/1,798,449$11.8M0.0%−244,497
Boston Partners1,683,885$11.0M0.0%New
Dixon Mitchell Investment Counsel Inc.1,545,956$10.1M0.3%+8,080
Quantinno Capital Management LP1,463,251$9.6M0.0%+474,261
Goldman Sachs Group Inc1,384,426$9.1M0.0%+499,216

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54